Strategic Acquisition Pharmaplan became part of Exyte in September 2024, signaling access to larger European pharma partnerships and a broader project ecosystem that can be leveraged to win mid to large-scale pharmaceutical manufacturing and biopharma facilities.

European Expansion Historic growth includes office expansion into Switzerland and Western Europe, indicating a regional demand spike and potential for localized project delivery, consulting, and engineering services across European life sciences hubs.

Integrated Capabilities Strong end-to-end offerings spanning project management, process engineering, GMP, lab design, automation, and digital factories position Pharmaplan to serve clients seeking turnkey facility development and advanced manufacturing digitalization.

Midmarket Revenue With revenue in the broad mid-market band and a workforce of 201–500, there is an opportunity to target mid-sized biopharma and contract manufacturing organizations seeking scalable, cost-efficient expertise for new facilities or expansions.

Industry Synergies As part of Exyte, Pharmaplan can cross-sell into high-tech sectors (biopharma, life sciences, semiconductors, data centers) leveraging cross-industry engineering excellence to win multi-disciplinary projects and long-term service contracts.